Form 4: Ullem Scott B. reports disposition transactions in EW

Rhea-AI Filing Summary

Ullem Scott B. reported disposition transactions in a Form 4 filing for EW. The filing lists transactions totaling 199 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 39,699 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ullem Scott B.

Role CVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	199	$75.87	$15K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 39,699 shares (Direct); Common Stock — 266,318 shares (Indirect, By Trust)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ullem Scott B.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/16/2026		F		199	D	$75.87	39,699	D
Common Stock								266,318	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EW CFO Scott B. Ullem report?

Scott B. Ullem reported a small tax-withholding disposition of 199 shares of Edwards Lifesciences common stock. The shares were used to cover an exercise price or tax liability, not as an open-market sale.

What was the price per share in Scott Ullem’s EW Form 4 transaction?

The reported tax-withholding disposition used Edwards Lifesciences shares valued at $75.87 per share. This price is the figure used in the Form 4 for the 199 shares applied toward the tax or exercise obligation.

How many EW shares does Scott Ullem directly own after this filing?

Following the reported transaction, Scott B. Ullem directly beneficially owned 39,699 shares of Edwards Lifesciences common stock. This figure reflects his direct holdings after using 199 shares for the tax-withholding disposition.

What are Scott Ullem’s indirect EW share holdings reported on this Form 4?

In addition to his direct holdings, Scott B. Ullem had indirect beneficial ownership of 266,318 shares of Edwards Lifesciences common stock. These shares are described as held “By Trust,” indicating they are owned through a trust structure.

Does the EW Form 4 show a buy or sell by Scott Ullem?

The filing shows a tax-withholding disposition coded as “F,” where 199 shares were delivered to cover an exercise price or tax liability. It does not represent a traditional open-market purchase or sale transaction.

What is Scott Ullem’s role at Edwards Lifesciences (EW) in this Form 4?

Scott B. Ullem is identified as an officer of Edwards Lifesciences, serving as CVP, Chief Financial Officer. The Form 4 reflects changes in his beneficial ownership of the company’s common stock as a reporting insider.